VASOPRESSIN IN 0.9% SODIUM CHLORIDE
Generic: VASOPRESSIN IN 0.9% SODIUM CHLORIDE
Baxter Healthcare CorporationManufacturer
INTRAVENOUSRoute
VASOPRESSINActive Substance
2023-09-29Original Approval
VASOPRESSIN IN 0.9% SODIUM CHLORIDE is FDA application NDA217569, sponsored by BAXTER HLTHCARE CORP. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2026-08-06
Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/mL), 100mL Single-Dose Container, Rx onlyCGMP Deviations
Class II2024-05-13
Vasopressin Injection, USP, 200 Units per 10 mL (20 Units per mL), 10 mL Multiple-Dose Vial, Rx only, For Intravenous ISubpotent product in addition to having out-of-specification results for impurities.
Class II2026-08-06
Vasopressin, in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), 100mL Single-Dose Container, Rx onlyCGMP Deviations
Top Reported Reactions
1
DRUG INEFFECTIVE
1,358 reports
2
OFF LABEL USE
551 reports
3
HYPOTENSION
509 reports
4
CARDIOGENIC SHOCK
427 reports
5
MULTIPLE ORGAN DYSFUNCTION SYNDROME
423 reports
6
SEPSIS
413 reports
7
CONDITION AGGRAVATED
401 reports
8
TOXICITY TO VARIOUS AGENTS
342 reports
9
ACUTE KIDNEY INJURY
340 reports
10
STRESS
319 reports